See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Baseball
Artificial Intelligence
Donald Trump
Vladimir Putin
Social Media
Republican Party
European Union
Soccer
Senate
Housing
Natural Disasters
Published • loading... • Updated

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma

Summary by JAMA Network
This randomized trial assesses the effect of adjuvant therapy with camrelizumab after chemoradiotherapy on 3-year event-free survival among patients with locoregionally advanced nasopharyngeal carcinoma.

1 Articles

All
Left
Center
Right
JAMA NetworkJAMA Network

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma

This randomized trial assesses the effect of adjuvant therapy with camrelizumab after chemoradiotherapy on 3-year event-free survival among patients with locoregionally advanced nasopharyngeal carcinoma.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

JAMA Network broke the news in on Tuesday, May 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Health

Health

News
For You
SearchBlindspotLocal